Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

19.60USD
16 Feb 2018
Change (% chg)

$0.20 (+1.03%)
Prev Close
$19.40
Open
$19.35
Day's High
$20.20
Day's Low
$19.23
Volume
176,718
Avg. Vol
274,671
52-wk High
$25.70
52-wk Low
$7.80

Latest Key Developments (Source: Significant Developments)

Bora Pharmaceuticals buys pharma firm owned by Impax Laboratories for $18.5 mln
Tuesday, 6 Feb 2018 02:25am EST 

Feb 6 (Reuters) - Bora Pharmaceuticals Co Ltd <6472.TWO> ::Says it completed acquisition of 100 percent stake in a pharmaceutical company owned by Impax Laboratories,Inc for $18.5 million .  Full Article

Impax Announces Sale Of Taiwan Manufacturing Facility
Tuesday, 19 Dec 2017 08:45am EST 

Dec 19 (Reuters) - Impax Laboratories Inc ::IMPAX ANNOUNCES SALE OF TAIWAN MANUFACTURING FACILITY.IMPAX LABORATORIES INC - ‍ ENTERED INTO A DEFINITIVE AGREEMENT TO SELL IMPAX TAIWAN TO BORA PHARMACEUTICALS CO​.IMPAX LABORATORIES - BORA WILL PURCHASE ALL OF ISSUED SHARE CAPITAL IN IMPAX TAIWAN, CERTAIN LOANS OUTSTANDING BETWEEN CO, UNIT FOR $18.5 MILLION..IMPAX LABORATORIES INC - AS A RESULT OF SALE, CO EXPECTS TO RECORD A PRE-TAX IMPAIRMENT CHARGE OF ABOUT $70.0 TO $80.0 MILLION IN Q4 OF THIS YEAR.IMPAX LABORATORIES INC - ‍AS A RESULT OF SALE, CO EXPECTS TO RECORD PRE-TAX IMPAIRMENT CHARGE OF ABOUT $70.0 TO $80.0 MILLION IN Q4 OF THIS YEAR​.IMPAX LABORATORIES INC - ‍ BORA WILL HAVE RIGHTS TO MARKET AND SELL IMPAX'S BRANDED PARKINSON'S DRUG RYTARY IN TAIWAN​.IMPAX - ALSO SIGNED SUPPLY AGREEMENT WITH BORA, EFFECTIVE UPON CLOSING OF TRANSACTION.IMPAX SAYS SIGNED SUPPLY AGREEMENT WITH BORA TO MANUFACTURE, SUPPLY OF CERTAIN OF CO'S MARKETED, DEVELOPMENT PRODUCTS CURRENTLY MANUFACTURED BY UNIT.  Full Article

Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules
Friday, 8 Dec 2017 07:30am EST 

Dec 8 (Reuters) - Impax Laboratories Inc ::IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES.IMPAX LABORATORIES INC - COMPANY'S ANDA IS ELIGIBLE FOR FINAL APPROVAL UPON EXPIRATION OF MARKETING EXCLUSIVITY ON MAY 7, 2018.  Full Article

Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​
Tuesday, 21 Nov 2017 05:22pm EST 

Nov 21 (Reuters) - Impax Laboratories Inc :Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​.Impax Laboratories Inc - ‍also entered into amendment no. 1 with K2 Merger Sub Corporation & Amneal Pharmaceuticals Llc​.Impax Laboratories Inc - ‍in connection with closing, Holdco will be renamed Amneal Pharmaceuticals, Inc.​.Impax Laboratories - ‍in connection with pipe transaction, amneal desires to revise capital structure of new amneal to provide for class B-1 stock​.  Full Article

Impax Q3 adjusted earnings per share $0.23
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Impax Laboratories Inc :Impax reports third quarter 2017 results.Q3 adjusted earnings per share $0.23.Q3 GAAP loss per share $0.69.Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S.Q3 revenue $206.4 million versus I/B/E/S view $208.4 million.Impax Laboratories Inc - sees ‍2017 adjusted gross margins as a percent of total revenue are expected to be approximately 47%​.Impax Laboratories Inc - sees ‍full year 2017 adjusted net income per share of $0.60 to $0.65​.FY2017 earnings per share view $0.70 -- Thomson Reuters I/B/E/S.Impax Laboratories Inc - sees 2017 ‍capital expenditures of approximately $25 million to $30 million​.Impax Laboratories Inc - ‍company narrows full year 2017 guidance​.Impax Laboratories Inc - ‍"while our Q3 results were in line with our expectations, we continue to navigate challenging generic market environment"​.Impax Laboratories Inc - ‍currently expect to complete closure of our Middlesex, New Jersey packaging facility by end of 2017, ahead of schedule​.Impax Laboratories Inc - ‍"we are in late-stage negotiations for sale of our Taiwan manufacturing facility​".Impax Laboratories - ‍if successful in selling Taiwan facility by end of Q1 of 2018, co could realize anticipated cost savings by end of 2018​.  Full Article

Impax gets FDA approval for generic Renvela tablets
Monday, 23 Oct 2017 04:01pm EDT 

Oct 23 (Reuters) - Impax Laboratories Inc :Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg.Impax Laboratories Inc - ‍impax has immediately initiated commercialization activities for a generic version of Renvela​.Impax Laboratories Inc - ‍sales of generic renvela are expected to benefit company's financial results this year​.  Full Article

IMPAX TO PAY AMNEAL $45 MLN IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​
Tuesday, 17 Oct 2017 10:15am EDT 

Oct 17 (Reuters) - Impax Laboratories Inc ::REQUIRED TO PAY AMNEAL FEE OF $45 MILLION IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​.AMNEAL TO BE ENTITLED TO REIMBURSEMENT FOR UP TO $15 MILLION EXPENSES, IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES - SEC FILING.  Full Article

Drugmaker Amneal to combine with Impax Labs
Tuesday, 17 Oct 2017 07:30am EDT 

Oct 17 (Reuters) - Impax Laboratories Inc :Amneal and Impax to combine.Transaction expected to generate $200 million of annual cost savings within three years​.Deal to be accretive to Impax's adjusted EPS within first 12 months​.Impax affirms 2017 financial guidance​.Amneal Holdings members to own about 75%, Impax shareholders to own about 25% of new co's pro forma shares on as converted basis​.Fy2017 earnings per share view $0.70, revenue view $800.8 million -- Thomson Reuters I/B/E/S.Combined company is expected to have 2018 pro forma adjusted EBITDA of approximately $700 million to $750 million​.Amneal's founders and co-chief executive officers, Chirag Patel & Chintu Patel, will serve as co-chairmen of combined co's board.‍Paul Bisaro, president and CEO of Impax, will serve as chief executive officer of combined company​.Co and ‍amneal Pharmaceuticals entered into a definitive business combination in an all-stock transaction​.Under terms of agreement, a new, publicly traded holding company, Amneal Pharmaceuticals Inc, will be formed​.Amneal Holdings members immediately prior to closing of transaction will receive non-economic, voting shares of Amneal Pharmaceuticals Inc​.Amneal Holdings members to be able to exchange membership units in Amneal Pharmaceuticals LLC for class A shares of Amneal Pharmaceuticals Inc​.Deal will be structured as "Up-C" deal with tax receivable agreement split 85% / 15% between Amneal Holdings members, Amneal Pharmaceuticals.  Full Article

Teligent announces FDA approval of partnered ANDA for Desonide Lotion
Monday, 2 Oct 2017 01:38pm EDT 

Oct 2 (Reuters) - Teligent Inc ::Teligent Inc announces FDA approval of partnered ANDA for Desonide Lotion, 0.05 pct.Says Desonide Lotion was submitted under a partnered development agreement by Teligent Inc With Impax Laboratories Inc​.Says currently plan to launch Desonide Lotion in Q4 of 2017.  Full Article

Impax Laboratories Q2 GAAP loss per share $0.28
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Impax Laboratories Inc :Impax reports solid second quarter 2017 results with total revenues increasing 17% to $202 million.Q2 adjusted earnings per share $0.18.Q2 GAAP loss per share $0.28.Q2 revenue $202.1 million versus I/B/E/S view $195.6 million.Q2 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Reaffirms full year 2017 EPS guidance​‍.2017 adjusted gross margins as a percent of total revenue are expected to be approximately 47% to 49%​.Sees 2017 ‍capital expenditures of approximately $25 million to $30 million​.Sees ‍full year 2017 adjusted net income per share of $0.55 to $0.70​.FY2017 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.  Full Article

Valeant unit, Impax lose Solodyn antitrust class action appeal

A federal appeals court has declined to review an order certifying a class action by purchasers of the acne medication Solodyn alleging Medicis Pharmaceutical Corp sought to delay the launch of generic versions of the drug in violation of antitrust laws.